Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697180 | 0.84 | GABRA1 (0.43) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| SCHEMBL245773 | 0.84 | GABRA1 (0.57) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| Ammonia Solution, Strong SCHEMBL27320869 | 0.81 | GABRA1 (0.55) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| Methylamine SCHEMBL27545014 | 0.81 | GABRA1 (0.55) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| SCHEMBL31498538 | 0.81 | GABRA1 (0.55) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| Methane SCHEMBL28776675 | 0.81 | GABRA1 (0.55) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| SCHEMBL2697186 | 0.81 | GABRA1 (0.40) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| SCHEMBL9000240 | 0.79 | GABRA1 (0.52) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| Hydrochloric Acid SCHEMBL4018938 | 0.79 | GABRA1 (0.52) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| Ethylene SCHEMBL27583042 | 0.79 | GABRA1 (0.52) | GABRA1GABRB2TAAR1HTR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117831652-A | Prediction method of olefin hydroformylation positive-to-negative ratio | 上海华谊控股集团有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116410239-A | Heteroatom-containing metallocene compound and preparation method and application thereof | 惠生(中国)投资有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-110818545-B | Method for preparing substituted aryl ketone by ketone arylation | 上海化工研究院有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-107963982-B | Polyisocyanate composition and isocyanate polymer composition | 旭化成株式会社 | 2021-11-12 | — | — | CN | claimed |
| CN-110818545-A | Method for preparing substituted aryl ketone by ketone arylation | 上海化工研究院有限公司 | 2020-02-21 | — | — | CN | claimed |
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1363955-B1 | MULTINUCLEAR METALLOCENE CATALYST | HONAM PETROCHEMICAL CORP (KR) | 2008-04-09 | — | — | EP | claimed |
| EP-1653960-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | claimed |
| US-6943225-B2 | Multinuclear metallocene catalyst | HONAM PETROCHEMICAL CORPORATION (KR) | 2005-09-13 | — | — | US | claimed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2004076502-A1 | SUPPORTED MULTINUCLEAR METALLOCENE CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PREPARING THE SAME | HONAM PETROCHEMICAL CORPORATION (KR) | 2004-09-10 | — | — | WO | claimed |
| US-20040072677-A1 | Multinuclear metallocene catalyst | HONAM PETROCHEMICAL CORPORATION (KR) | 2004-04-15 | — | — | US | claimed |
| EP-1363955-A1 | MULTINUCLEAR METALLOCENE CATALYST | Honam Petrochemical Corporation (KR) | 2003-11-26 | — | — | EP | claimed |
| WO-2002060964-A1 | MULTINUCLEAR METALLOCENE CATALYST | HONAM PETROCHEMICAL CORPORATION (KR) | 2002-08-08 | — | — | WO | claimed |
| US-5840646-A | Olefin polymerization catalyst component | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-24 | — | — | US | claimed |
| CN-118302407-A | Carbonyl compound, method for producing isocyanate compound, and isocyanate composition | 旭化成株式会社 | 2024-07-05 | — | — | CN | disclosed |
| CN-118215651-A | Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition | 旭化成株式会社 | 2024-06-18 | — | — | CN | disclosed |
| EP-0761694-A1 | Olefin polymerization catalyst component, olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0235523-A2 | Dichlorobenzodioxenes | BAYER AG (DE) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | MCHR1, MC1R, NPY1R | GABRA1 676/4885GABRB2 1002/4885TAAR1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.